Literature DB >> 33820824

Genome-Wide Analysis of Experimentally Evolved Candida auris Reveals Multiple Novel Mechanisms of Multidrug Resistance.

Hans Carolus1,2, Siebe Pierson2, José F Muñoz3, Ana Subotić1,2, Rita B Cruz2, Christina A Cuomo3, Patrick Van Dijck4,2.   

Abstract

Candida auris is globally recognized as an opportunistic fungal pathogen of high concern, due to its extensive multidrug resistance (MDR). Still, molecular mechanisms of MDR are largely unexplored. This is the first account of genome-wide evolution of MDR in C. auris obtained through serial in vitro exposure to azoles, polyenes, and echinocandins. We show the stepwise accumulation of copy number variations and novel mutations in genes both known and unknown in antifungal drug resistance. Echinocandin resistance was accompanied by a codon deletion in FKS1 hot spot 1 and a substitution in FKS1 "novel" hot spot 3. Mutations in ERG3 and CIS2 further increased the echinocandin MIC. Decreased azole susceptibility was linked to a mutation in transcription factor TAC1b and overexpression of the drug efflux pump Cdr1, a segmental duplication of chromosome 1 containing ERG11, and a whole chromosome 5 duplication, which contains TAC1b The latter was associated with increased expression of ERG11, TAC1b, and CDR2 but not CDR1 The simultaneous emergence of nonsense mutations in ERG3 and ERG11 was shown to decrease amphotericin B susceptibility, accompanied with fluconazole cross-resistance. A mutation in MEC3, a gene mainly known for its role in DNA damage homeostasis, further increased the polyene MIC. Overall, this study shows the alarming potential for and diversity of MDR development in C. auris, even in a clade until now not associated with MDR (clade II), stressing its clinical importance and the urge for future research.IMPORTANCE Candida auris is a recently discovered human fungal pathogen and has shown an alarming potential for developing multi- and pan-resistance toward all classes of antifungals most commonly used in the clinic. Currently, C. auris has been globally recognized as a nosocomial pathogen of high concern due to this evolutionary potential. So far, this is the first study in which the stepwise progression of multidrug resistance (MDR) in C. auris is monitored in vitro Multiple novel mutations in known resistance genes and genes previously not or vaguely associated with drug resistance reveal rapid MDR evolution in a C. auris clade II isolate. Additionally, this study shows that in vitro experimental evolution can be a powerful tool to discover new drug resistance mechanisms, although it has its limitations.
Copyright © 2021 Carolus et al.

Entities:  

Keywords:  Candida auris; amphotericin B; antifungal agents; caspofungin; drug resistance evolution; experimental evolution; fluconazole; genome analysis; microevolution; multidrug resistance; whole-genome sequencing

Year:  2021        PMID: 33820824     DOI: 10.1128/mBio.03333-20

Source DB:  PubMed          Journal:  mBio            Impact factor:   7.867


  14 in total

1.  Genomic landscape of the DHA1 family in Candida auris and mapping substrate repertoire of CauMdr1.

Authors:  Rosy Khatoon; Suman Sharma; Poonam Vishwakarma; Amandeep Saini; Parth Aggarwal; Andrew M Lynn; Amresh Prakash; Rajendra Prasad; Atanu Banerjee
Journal:  Appl Microbiol Biotechnol       Date:  2022-10-03       Impact factor: 5.560

2.  Comparative Transcriptomics Reveal Possible Mechanisms of Amphotericin B Resistance in Candida auris.

Authors:  Raju Shivarathri; Sabrina Jenull; Manju Chauhan; Ashutosh Singh; Rounik Mazumdar; Anuradha Chowdhary; Karl Kuchler; Neeraj Chauhan
Journal:  Antimicrob Agents Chemother       Date:  2022-06-02       Impact factor: 5.938

3.  Bioinformatic Identification of ABC Transporters in Candida auris.

Authors:  Atanu Banerjee; Poonam Vishwakarma; Naveen Kumar Meena; Andrew M Lynn; Rajendra Prasad
Journal:  Methods Mol Biol       Date:  2022

Review 4.  Caspofungin resistance in Candida albicans: genetic factors and synergistic compounds for combination therapies.

Authors:  Francine Perrine-Walker
Journal:  Braz J Microbiol       Date:  2022-03-29       Impact factor: 2.214

Review 5.  Using genomics to understand the mechanisms of virulence and drug resistance in fungal pathogens.

Authors:  Miquel Àngel Schikora-Tamarit; Toni Gabaldón
Journal:  Biochem Soc Trans       Date:  2022-06-30       Impact factor: 4.919

6.  Transcriptional Response of Candida auris to the Mrr1 Inducers Methylglyoxal and Benomyl.

Authors:  Amy R Biermann; Deborah A Hogan
Journal:  mSphere       Date:  2022-04-27       Impact factor: 5.029

7.  Impact of FKS1 Genotype on Echinocandin In Vitro Susceptibility in Candida auris and In Vivo Response in a Murine Model of Infection.

Authors:  Dipti Sharma; Raees A Paul; Shivaprakash M Rudramurthy; Nisha Kashyap; Sanjay Bhattacharya; Rajeev Soman; Shamanth A Shankarnarayan; Dipali Chavan; Shreya Singh; Parijit Das; Harsimran Kaur; Anup K Ghosh; Rajendra Prasad; Kaustuv Sanyal; Arunaloke Chakrabarti
Journal:  Antimicrob Agents Chemother       Date:  2021-11-15       Impact factor: 5.938

Review 8.  Candida auris and other phylogenetically related species - a mini-review of the literature.

Authors:  Cristina Nicoleta Ciurea; Anca Delia Mare; Irina-Bianca Kosovski; Felicia Toma; Camelia Vintilă; Adrian Man
Journal:  Germs       Date:  2021-09-29

Review 9.  Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis.

Authors:  Sarah E Murphy; Tihana Bicanic
Journal:  Front Cell Infect Microbiol       Date:  2021-12-14       Impact factor: 6.073

10.  Narrow mutational signatures drive acquisition of multidrug resistance in the fungal pathogen Candida glabrata.

Authors:  Ewa Ksiezopolska; Miquel Àngel Schikora-Tamarit; Reinhard Beyer; Juan Carlos Nunez-Rodriguez; Christoph Schüller; Toni Gabaldón
Journal:  Curr Biol       Date:  2021-10-25       Impact factor: 10.834

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.